Drug Trial Radar · NCT07421700
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Mar 11, 2026
Primary completion
Dec 28, 2027
Study completion Sep 25, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma Inc
- First posted
- Feb 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The purpose of the study is to see if PF-08634404 is safe, how well it works, how it moves through the body, and how it affects the cancer. The study will also look at how the medicine may change certain markers in the body that are linked to cancer. To join the study, participants must: * Be adults (18 years or older) and * Have locally advanced or metastatic urothelial cancer, The study has two groups: * Cohort A: People who have already received treatment for their cancer will get the study medicine ( PF-08634404) alone. * Cohort B: People who have not had treatment before will get the study medicine along with another cancer medicine called enfortumab vedotin. Everyone in the study will get the study medicine through a vein (IV infusion) with or without enfortumab vedotin. Treatment will continue as long as it helps and side effects are manageable. Before starting, participants will go through a screening period to check if they are eligible. During the study, they will have regular visits for treatment, health checks, and tests to see how the cancer is responding. Scans will be done regularly to monitor the cancer. If the cancer gets worse but the treatment is still helping and side effects are manageable, participants may be allowed to continue treatment with their doctor's and the sponsor's agreement.
Conditions
- Urothelial Cancer
- Advanced/Metastatic Urothelial Cancer
- Urothelial Carcinoma
Interventions
PF-08634404Biological
Concentrate for solution for Infusion.
Enfortumab VedotinBiological
Powder for concentrate for solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Objective Response Rate (ORR) by investigatorTime frame: Up to approximately 3 years
- Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Through 90 days after the last study intervention; Up to approximately 3 years
- Number of participants with dose limiting toxicity (DLT) in Part 1 of Cohort BTime frame: Through 90 days after the last study intervention; Up to approximately 3 years
Locations
184 sites in 6 countries. Site status is shown where the registry gives one.
Highlands Oncology Group, PA
Fayetteville, Arkansas · Recruiting
Highlands Oncology Group, PA
Rogers, Arkansas · Recruiting
Highlands Oncology Group, PA
Springdale, Arkansas · Recruiting
UCLA Hematology/Oncology - Alhambra
Alhambra, California · Recruiting
UCLA Hematology/Oncology - Atascadero
Atascadero, California · Recruiting
UCLA Hematology/Oncology - Beverly Hills
Beverly Hills, California · Recruiting
UCLA Hematology/Oncology - Burbank
Burbank, California · Recruiting
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California · Recruiting
City of Hope Investigational Drug Services (IDS)
Duarte, California · Recruiting
UC San Diego Medical Center - Encinitas
Encinitas, California · Recruiting
UCLA Hematology/Oncology - Encino
Encino, California · Recruiting
UCLA Hematology/Oncology - Irvine
Irvine, California · Recruiting
Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
UCI Health - Irvine Infusion Pharmacy ACC
Irvine, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
City of Hope Investigational Drug Service (IDS)
Irvine, California · Recruiting
UC San Diego Koman Family Outpatient Pavilion
La Jolla, California · Recruiting
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
La Jolla, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
UC San Diego Shiley Eye Institute
La Jolla, California · Recruiting
UC San Diego Sulpizio Cardiovascular Center
La Jolla, California · Recruiting
Viterbi Family Department of Ophthalmology
La Jolla, California · Recruiting
UCLA Hematology Oncology- Laguna Hills
Laguna Hills, California · Recruiting
City of Hope-Long Beach (ELM)
Long Beach, California · Recruiting
START Los Angeles, LLC
Los Angeles, California · Recruiting
Los Angeles Cancer Network - Century City
Los Angeles, California · Recruiting
(IRB# 26-0433) Ronald Reagan UCLA Medical Center, Drug Information Center
Los Angeles, California · Recruiting
UCLA Hematology/Oncology
Los Angeles, California · Recruiting
UCLA Hematology/Oncology - Marina del Rey
Marina del Rey, California · Recruiting
UC Irvine Health
Orange, California · Recruiting
UCLA Hematology/Oncology - Pasadena
Pasadena, California · Recruiting
UCLA Hematology Oncology - Porter Ranch
Porter Ranch, California · Recruiting
UC San Diego Medical Center - Bankers Hill
San Diego, California · Recruiting
UC San Diego McGrath Outpatient Pavilion - Hillcrest
San Diego, California · Recruiting
UC San Diego Medical Center- Hillcrest
San Diego, California · Recruiting
UC San Diego Medical Center - Rancho Bernardo
San Diego, California · Recruiting
UCLA Hematology/Oncology - San Luis Obispo
San Luis Obispo, California · Recruiting
UCLA Hematology/Oncology- Santa Barbara
Santa Barbara, California · Recruiting
UCLA Hematology/Oncology- Santa Monica
Santa Monica, California · Recruiting
UCLA Hematology/Oncology - Torrance
Torrance, California · Recruiting
Showing 40 of 184 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.